Glimepiride 1mg + Metformin 500mg SR Bilayered Tablets are a solid oral dosage form that combines the API Glimepiride 1mg with Metformin 500mg to produce a Bilayered tablet dosage form. The formulation is engineered through specific manufacturing processes that result in two APIs being incorporated as separate layers whilst retaining the specified ratio and physical characteristics of the final formulated product.
The use of multiple layers in the dosage form requires formulation to support its physical and chemical characteristics such as powder flow, compression characteristics, interlayer bonding and tablet strength. The controlled-release aspect of the product also requires the formulation to support repeatable dissolution behavior, depending on the formulation design.
Companies in the pharmaceutical industry offering a structured formulary for tableted active pharmaceutical ingredients can list Glimepiride 1mg + Metformin 500mg SR Bilayered Tablets as a professionally formulated product in a PCD Pharma Franchise portfolio.
The manufacture of Glimepiride 1mg + Metformin 500mg SR Bilayered Tablets begins with pharmaceutical quality API qualification. Both Glimepiride and Metformin are qualified based on raw-material specifications, quality control tests and release approval criteria, preparing the APIs for incorporated into finished formulation.
The formulation must then support the differences in processing of these two APIs as well as the physical and chemical characteristics of the finished dosage form. Appropriate excipients are selected for physical properties such as flow, binding and disintegration as well as a diluent matrix for sustained-release if applicable.
The core Metformin formulation is then developed to support a controlled-release profile while the API is incorporated into the final coating. Glimepiride is used in the other formulation layer based on the finalized design specification.
The accurate weighing of active ingredients, adjusted for the difference in strength, during dispensing requires calibrated equipment and well-documented procedures.
Bilayer compression of two distinct formulation blends or granulations allows for the separation of the high dose and low dose APIs within individual tablets. Each layer must be prepared separately, weighed and transferred into the compression machine using controlled methods.
Each layer is carefully compressed to form the final Bilayered dosage form, with each tablet positioned within the compression machine so that the two layers form a compatible unit. The compression parameters (force, dwell time, machine speed), the target weight for each individual layer, as well as the total weight of the finished tablet, can influence the physical and drug-release characteristics of the final drug product.
The Metformin-containing layer can be composed of either a sustained-release matrix material or another modified-release technology developed during the formulation process. The API-specific formulation can then be incorporated into the film or matrix system. Glimepiride is used in its designated layer in the finalized formulation.
Dosage form accuracy is important to determine that the two APIs are incorporated at the correct strength. Appropriate controlled weighing methods can be employed during preparation and manufacturing to maintain the accuracy of the dosage units.
The individual formulation blends are prepared to contain the APIs at their required concentrations in the targeted formulation. The individual blends are separately processed to support their physical flowability and compressibility before being transferred into the bilayer compression machine. Granulation, milling, sizing, lubricating may be part of this process.
The two formulation layers are maintained as separate entities until they are compressed together, maintaining their two-component nature in each finished tablet. Strict control of the batching processes, transfer, and compression is necessary to preserve each layer in the desired formation.
In-process testing may include tablet weight for each layer, final weight, hardness, thickness, appearance, disintegration for the non-controlled-release component, layer integrity, and other relevant quality parameters. Visual assessment of the bilayer morphology can be used to check for adhesion and layer separation or damage such as chipping or capping.
Capital equipment such as compression machinery is calibrated and maintained according to documented procedures. Batch details are recorded including API quantities, formulations, weights, compression pressures and other pertinent data.
Because the product formulation involves a relatively low-dose API in combination with a higher strength API, blending and sampling procedures can be implemented for uniform quality.
Product quality control covers testing of the finished product for physical and chemical parameters at the beginning and end of the shelf-life. Quality control tests on the finished bilayer dosage form may include content, assay of each API, impurity profiling, disintegration, dissolution, foreign particle examination, appearance, weight, and other specified tests.
The release testing is particularly important for the sustained-release aspect of the formulation, with sampling at specified points in time allowing calculation of the release profile. The drug release profile can then be compared to the product specification.
Content uniformity testing can be employed to document the consistency of the API composition from dosage to dosage, especially for the Glimepiride component at the lower dose.
Stability testing allows the storage of the finished dosage form to be simulated under relevant storage conditions, during which time properties such as appearance, API content, impurity levels, dissolution, physical integrity and release profile are monitored over the approved shelf-life period.
Appropriate packaging materials are selected based on the stability profile of the formulation. Formulation may be incorporated into blister packs, tubes or bottles with appropriate secondary packaging and protective packaging to avoid physical damage during distribution. Proper labeling ensures the identification of products, carry expiry date and batch information, storage requirements and other pertinent details.
As an organization working within the framework of PCD Pharma Franchise, pharmaceutical companies can fit Glimepiride 1mg + Metformin 500mg SR Bilayered Tablets into their structured product portfolio by sourcing the active pharmaceutical ingredient, developing the formulation for the two components, optimizing the compression and design for the final drug product, releasing after quality testing and stability monitoring, and finally packaging the product appropriately.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech